A significant number of patients with acute myeloid leukemia (AML) are unable to withstand intensive chemotherapy regimens due to older age and the presence of comorbidities, creating an unmet medical need. Recent advances in the understanding of the genomics underlying AML have led to the development of therapies targeting FLT3, IDH1/2 and BCL-2. Between 2017 and 2018 the US FDA approved a total of eight drugs for AML, including glasdegib, venetoclax, ivosidenib, midostaurin and gemtuzumab ozogamicin. Many trials are now reporting longer follow-up data on these drugs as well as on novel combinations and approaches.
In this podcast, Andrew Brunner, MD, of the Massachusetts General Hospital, Boston, MA, Mark Levis, MD, PhD, of the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Stéphane de Botton, MD, PhD, of the Gustave Roussy Institute, Paris, France, and Andrius Zucenka, MD, of the Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, share updates on novel therapies for the treatment of AML, as presented at the European Hematology Association (EHA) 2021 congress.
iwMyeloma 2024 Session I: approaching bone disease, clinical trial updates & the value of MRD as an endpoint in trials
Managing anemia in MF, key emerging trials in the UK, and approaching young patients with MPNs
Highlights from EBMT 2024: treating & managing GvHD & understanding the role of the gut microbiome
The importance of cardio-oncology: awareness around the ESC 2022 guidelines & the value of building MDTs
Exploring the possibility of early interception in smoldering myeloma: novel agents, challenges & advances in risk stratification
CHIP & CCUS: knowledge gaps, ongoing trials & recommendations for approaching patients with myeloid precursors
Monoclonal B-cell lymphocytosis: classification, biology and exploring the possibility of early interception
The impact of CAR-T therapy on the myeloma treatment landscape, patient selection for CAR-T & the evolving role of autoSCT
Diagnosing amyloidosis, currently available therapies & the importance of cardio-oncology
Addressing the importance of lymphodepletion, factors contributing to ICAHT & the cost effectiveness of CAR-T therapy
Updates with the use of CAR-T therapy in ALL: ongoing challenges, strategies to overcome resistance & future outlooks
Targeted therapy in AML: the growing role of menin inhibitors & clinical trials exploring these agents
Updates in lower- and higher-risk MDS: challenges, novel agents & key clinical trials at ASH 2023
Key updates in thalassemia at ASH 2023: gene therapies, ongoing trials & the value of precision medicine
Updates, challenges and novel agents being explored in BPDCN
Unanswered questions regarding the sequencing of BCMA therapies, the prognostic value of CTCs & the growing role of quadruplets
Key updates in sickle cell disease at ASH 2023: disease biology, ongoing trials & the growing role of gene therapy
ASH 2023 highlights: updates in the diagnosis and treatment of amyloidosis
MPN highlights at ASH 2023: novel agents & ongoing clinical trials in ET, PV and MF
iwNHL 2023 Session V: Expanding the CAR platform in NHL
Create your
podcast in
minutes
It is Free
The Relaxback UK Show
Good Nurse Bad Nurse
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive